140例女性疑似生殖器疱疹患者HSV-Ⅱ抗体检测分析

目的:了解女性疑似生殖器疱疹GH患者感染生殖器疱疹发病情况。方法:对140例女性疑似生殖器疱疹患者血清检测HSV-Ⅱ-IgG抗体,并与140例正常人群作对照检测。结果:140例高危人群血清HSV-Ⅱ抗体阳性率为15%,正常人群阳性率为1.4%,两组阳性率比较有显著性差异(2=17.10,P<0.01)。结论:在性病门诊,对有多个性伴或性伴感染生殖器疱疹的女性高危人群在GH临床症状不明显时,应进行血清HSV-Ⅱ抗体检测。     

177例可疑生殖器疱疹患者HSV-ⅡIgM/IgG抗体检测结果分析

目的:探讨Ⅱ型单纯疱疹病毒抗体(HSV-ⅡIgM/IgG)与生殖器疱疹的相关性,辅助临床诊断。方法:应用酶联免疫吸附试验(ELISA)检测血清中HSV-ⅡIgM/IgG抗体,并用PCR荧光定量法检测分泌物的HSV-Ⅱ抗原(HSV-Ⅱ-DNA)进行对比。结果:177例可疑生殖器疱疹患者检出HSV-Ⅱ抗原131例,阳性率为74.0%;检出HSV-ⅡIgM和(或)IgG共144例,阳性率为81.4%,两者没有显著性差异(2=2.96,P>0.05)。其中19例为结痂型的患者中,HSV-Ⅱ抗原阳性4例,阳性率21.1%;而HSV-Ⅱ抗体阳性14例,阳性率为73.7%。结论:同时检测血清中HSV-ⅡIgG和HSV-ⅡIgM作为生殖器疱疹筛查试验,有利于症状不典型的HSV-Ⅱ感染者的检出,提高诊断率。     

女性原发性生殖器疱疹中HSV-Ⅱ的检测及意义

目的探讨单纯疱疹病毒Ⅱ型(HSV-Ⅱ)与女性原发性生殖器疱疹(GH)的相关性及意义。方法应用酶联免疫吸附法(ELISA)分别检测患者血清中HSV-Ⅱ抗体以及分泌物中的HSV-Ⅱ抗原。结果HSV-Ⅱ中IgG均阴性的138例女性生殖器疱疹患者中HSV-Ⅱ抗原阳性78例(56.52%);HSV-Ⅱ中IgM抗体阳性130例(94.20%),抗体阳性率明显高于抗原阳性率(P<0.01)。典型病例组抗原阳性65例(87.84%),IgM抗体阳性66例(89.19%);不典型病例组抗原阳性13例(20.31%),IgM抗体阳性64例(100.00%)。结论对于皮损时间短,症状典型者可检测HSV-Ⅱ抗原;皮损时间长,或反复者可检测HSV-Ⅱ抗体,可以有效提高HSV感染的临床诊断率。     

酶联免疫吸附试验检测单纯疱疹病毒抗体在生殖器疱疹筛查中的应用

目的:探讨酶联免疫吸附试验检测单纯疱疹病毒(HSV)抗体对生殖器疱疹筛查的意义。方法:选取50例2010年2月至2013年10月来我院治疗疑似生殖器疱疹患者,将其作为试验组,使用酶联免疫吸附试验进行HSV抗体检测,另外选择50例健康体检人员血清作为对照组。结果:在50例疑似生殖器疱疹患者HSV-I Ig M,HSV-I Ig G的检出率依次为14%,32%,HSV-ⅡIg M检出率为20%,HSV-ⅡIg G的检出率为34%;在对照组中HSV-I Ig M,HSV-I Ig G的检出率依次为0.8%,14%,HSV-ⅡIg M检出率为10%,HSV-ⅡIg G的检出率为24%,两组患者HSV抗体检测阳性率有显著的不同,二者明显的差异具有统计学意义(P0.05)。结论:疑似生殖器疱疹患者单纯疱疹病毒抗体检出率高,酶联免疫检测HSV抗原的方法可直接检测出泌尿生殖道及皮损中HSV病原体,在生殖器疱疹筛查中具有一定的优势。     

不同人群单纯疱疹病毒2型IgG抗体的检测情况分析

目的:了解珠海市一般人群、无症状可疑生殖器疱疹患者及有症状可疑生殖器疱疹患者血清单纯疱疹病毒2型(HSV-2)IgG抗体感染水平。方法:应用酶标仪对一般人群、无症状可疑患者、有症状可疑患者三组人群进行HSV-2IgG抗体检测,分析三组人群HSV-2的感染率,并比较无症状与有症状可疑生殖器疱疹患者血清学的状况。结果:在96名一般人员中HSV-2IgG抗体阳性率13.54%,175例无症状可疑患者HSV-2IgG抗体阳性率57.1%,174例有症状可疑患者HSV-2IgG抗体阳性率72.41%。结论:HSV-2IgG抗体对无症状可疑患者和中、后期及复发有症状患者具有协助诊断的意义。     

评价在辅助生育中检测单纯疱疹病毒2抗体对诊断生殖器疱疹的意义

【摘要】 目的 在分析生殖器疱疹患者单纯疱疹病毒（HSV）流行株的基础上,探讨HSV-2 IgM抗体、型特异HSV-2 IgG抗体的敏感性、特异性、阴性预测值和阳性预测值,评价辅助生育中二种抗体检测在诊断生殖器疱疹上的意义。 方法 对2009—2011年中山大学附属第一医院皮肤科193例生殖器疱疹患者临床分离病毒株培养并鉴定分型,了解主要的流行病毒型。生殖中心术前筛查HSV-2 IgM和（或）IgG阳性、疑诊生殖器疱疹的女性,丈夫同时抽血检查,共57对为临床观察组;选取HSV培养阳性生殖器疱疹患者68例作为阳性对照组;8 ~ 10岁儿童120例为阴性对照组。血清标本采用酶联免疫吸附法（ELISA）检测HSV-1 IgM和HSV-2 IgM抗体及型特异HSV-1 IgG、HSV-2 IgG抗体,对结果进行比对分析。 结果 阳性对照组68例中,HSV-1 IgM 14例（20.59%）、HSV-2 IgM 9例（13.24%）、HSV-1 IgG 61例（89.71%）、HSV-2 IgG 62例（91.18%）阳性;阴性对照组120例,分别为26例（21.70%）、16例（13.30%）、49例（40.80%）和0例阳性;两组HSV-1 IgM及HSV-2 IgM阳性率差异均无统计学意义（P > 0.05）,但HSV-1 IgG及HSV-2 IgG阳性率差异均有统计学意义（P < 0.01）。临床观察组57例女性中,HSV-1 IgM 46例（80.70%）、HSV-2 IgM 52例（91.23%）、HSV-1 IgG 48例（84.21%）、HSV-2 IgG 8例（14.04%）阳性;男性（配偶）分别为11例（19.30%）、5例（8.77%）、50例（87.71%）和7例（12.28%）阳性;两性的HSV-1 IgM及HSV-2 IgM阳性率差异均有统计学意义（P < 0.01）,而HSV-1 IgG及HSV-2 IgG阳性率差异均无统计学意义（P > 0.05）。HSV-2 IgM诊断生殖器疱疹的敏感性为13.24%,特异性为86.67%,阳性预测值36.00%,阴性预测值63.80%;HSV-2 IgG诊断生殖器疱疹的敏感性91.18%,特异性100.00%,阳性预测值100.00%,阴性预测值95.24%。 结论 该地区生殖器疱疹主要流行病毒型为HSV-2,仅5.18%是HSV-1。HSV-2 IgM诊断生殖器疱疹的敏感性、阳性预测值以及特异性、阴性预测值均低于HSV-2 IgG;辅助生育中型特异性HSV-2 IgG检测在诊断生殖器疱疹上的意义大于HSV-2 IgM。 【关键词】 疱疹,生殖器; 单纯疱疹病毒属; 免疫球蛋白G; 免疫球蛋白M     

生殖器疱疹患者530例HSV抗体型别检测分析

目的了解生殖器疱疹患者HSV-1和HSV-2的感染情况,并分析生殖器疱疹的流行特点。方法采用酶联免疫吸附试验(ELISA)法对性病门诊530例临床诊断为生殖器疱疹的患者进行了HSV血清抗体检测。结果 530例中男311例(58.68%),女219例(41.32%)。HSV-1IgM抗体阳性60例(11.32%),HSV-1IgG抗体阳性471例(88.87%),HSV-2IgM抗体阳性213例(40.19%),HSV-2IgG抗体阳性349例(65.85%)。年龄以31～40岁最多,为210例,其次为21～30岁194例。职业中最多的是自由职业和民工。初发者304例(57.36%),复发者226例(42.64%),其中频繁发作(≥6次/年)85例(16.04%)。结论长春地区生殖器疱疹患者以HSV-2感染为主。女性近期感染多于男性。以21～40岁性活跃人群为高发年龄组。     

生殖器疱疹无症状排毒与血清抗体及药物干预的研究

目的 探讨生殖器疱疹患者无症状排毒与血清抗体及药物干预的相关性.方法 收集生殖器疱疹患者650例,分别用荧光PCR和酶联免疫法(ELISA)测定排毒率、质粒数和不同病程、不同复发频率的生殖器疱疹患者无症状排毒阳性情况及血清抗体(IgG和IgM)的分泌情况,药物干预后的排毒情况和复发评价.结果 入选的650例患者中,排毒阳性354例(54.5％),DNA质粒数为63～ 9400拷见/ml,平均3100拷贝/ml.病程超过3年与小于3年的患者比较,排毒阳性率差异有统计学意义(x2=6.41,P＜0.05).频发(每年复发频率＞6次)与少发患者比较,差异有统计学意义(x2=9.46,P＜0.01).排毒阳性与阴性患者HSV-Ⅰ和ⅡIgG双阳性率、HSV-Ⅰ IgG单阳性率比较,差异均有统计学意义(P＜ 0.01); HSV-ⅡIgM单阳性率比较,差异无统计学意义(P＞0.05).对排毒阳性患者进行药物干预,伐昔洛韦组、阿昔洛韦组与对照组比较,干预后的排毒阳性率差异均有统计学意义(P＜0.01),停药后与对照组比较无统计学意义(P＞0.05).药物干预能够明显降低患者复发次数,而药物干预组间没有差异(P＞0.05).结论 生殖器疱疹患者无症状排毒率高达54.5％,血清学检测提示,部分生殖器疱疹患者存在HSV-Ⅰ及HSV-Ⅱ混合感染.患者病程越长阳性检测率越低,排毒阳性患者用药干预后能明显降低患者复发,抑制患者排毒.     

不同孕期治疗孕妇生殖器疱疹对阻断新生儿感染的影响

目的探讨妊娠合并生殖器疱疹患者在不同时间进行治疗后的孕妇所生的新生儿生殖器疱疹阳性率的不同。方法对本院2001年1月-2009年12月确诊生殖器疱疹患者进行回顾性分析,其中妊娠前及妊娠中发现并进行治疗者133例,妊娠中发现未能进行治疗者47例。妊娠前患生殖器疱疹的妇女予口服抗病毒药及外用干扰素软膏和阿昔洛韦软膏治疗,妊娠中患生殖器疱疹的妇女予外用干扰素软膏和阿昔洛韦软膏治疗。新生儿在出生后随访3周,监测临床表现,并抽血查HSV-2抗体(IgG和IgM)以观察阳性情况。结果妊娠前进行治疗的孕妇所生新生儿的HSV-2抗体阳性率为2.26%(3/133),而未治疗患者新生儿抗体阳性率为17.02%(8/47),两者之间差异有统计学意义(P<0.005)。结论对于妊娠患有生殖器疱疹者,早期进行足量抗病毒治疗可以有效的防止胎儿感染生殖器疱疹。     

复发性生殖器疱疹的治疗体会

生殖器疱疹(genital herpes,GH)是一类由单纯疱疹病毒(HSV)感染引起的性传播疾病.GH病原体90％是由单纯疱疹病毒Ⅱ型(HSV-Ⅱ)引起,10％是1型单纯疱疹病毒(HSV-Ⅰ)引起[1].患者发病后,呈现出终身复发性感染.有关资料表明,有大约90％以上的因HSV-Ⅱ初次感染的患者,会在随后的1年内出现复发,复发次数的中位数大约为4次.GH感染者年纪越小,其复发的可能性越高.目前,还没有控制GH复发的特效疫苗以及方法.因此,探讨及研究针对复发性生殖器疱疹的治疗方法在现阶段尤为重要.我院近些年采用泛昔洛韦片口服及干扰素局部注射治疗复发性生殖器疱疹患者,取得了非常好的效果,现报道如下.     

New fillers for the new man

ABSTRACT:  Two new collagen-based lidocaine-containing dermal fillers, ArteSense™/ArteFill™ (Artes Medical, San Diego, CA) and Evolence® (Colbar LifeScience Ltd., Herzliya, Israel), have proved to be of particular interest to men, many of whom seek a long-lasting or permanent correction. ArteFill™ has been available in the United States since 2006, and it is expected that Evolence® will reach the American market in 2008. The properties of the two products will be described, and experience based on the administration of many hundreds of syringes of both products by a Canadian dermatologist will be detailed here, with tips and precautions to optimize patient outcomes.     

Outcomes and adverse effects of ablative vs nonablative lasers for skin resurfacing: A systematic review of 1093 patients

It is generally believed that ablative laser therapies result in prolonged healing and greater adverse events when compared with nonablative lasers for skin resurfacing. To evaluate the efficacy of ablative laser use for skin resurfacing and adverse events as a consequence of treatment in comparison to other modalities, a PRISMA‐compliant systematic review (Systematic Review Registration Number: 204016) of twelve electronic databases was conducted for the terms “ablative laser” and “skin resurfacing” from March 2002 until July 2020. Studies included meta‐analyses, randomized control trials, cohort studies, and case reports to facilitate evaluation of the data. All articles were evaluated for bias. The search strategy produced 34 studies. Of 1093 patients included in the studies of interest, adverse events were reported in a total of 106 patients (9.7%). Higher rates of adverse events were described in nonablative therapies (12.2% ± 2.19%, 31 events) when compared with ablative therapy (8.28% ± 2.46%, 81 events). 147 patients (13.4%) reported no side effects, 68 (6.22%) reported expected, transient self‐resolving events, and five (0.046%) presented with hypertrophic scarring. Excluding transient events, ablative lasers had fewer complications overall when compared with nonablative lasers (2.56% ± 2.19% vs 7.48% ± 3.29%). This systematic review suggests ablative laser use for skin resurfacing is a safe and effective modality to treat a range of pathologies from photodamage and acne scars to hidradenitis suppurativa and posttraumatic scarring from basal cell carcinoma excision. Further studies are needed, but these results suggest that ablative lasers are a superior, safe, and effective modality to treat damaged skin.     

Genetic alterations in RAS‐regulated pathway in acral lentiginous melanoma

Studies integrating clinicopathological and genetic features have revealed distinct patterns of genomic aberrations in Melanoma. Distributions of BRAF or NRAS mutations and gains of several oncogenes differ among melanoma subgroups, while 9p21 deletions are found in all melanoma subtypes. In the study, status of genes involved in cell cycle progression and apoptosis was evaluated in a panel of 17 frozen primary acral melanomas. NRAS mutations were found in 17% of the tumors. In contrast, BRAF mutations were not found. Gains of AURKA gene (20q13.3) were detected in 37.5% of samples, gains of CCND1 gene (11q13) or TERT gene (5p15.33) in 31.2% and gains of NRAS gene (1p13.2) in 25%. Alterations in 9p21 were identified in 69% of tumors. Gains of 11q13 and 20q13 were mutually exclusive, and 1p13.2 gain was associated with 5p15.33. Our findings showed that alterations in RAS‐related pathways are present in 87.5% of acral lentiginous melanomas.     

Self‐resolving superficial primary cutaneous mucormycosis in a 7‐week‐old infant

A 7‐week‐old girl, born at 30 weeks' gestational age, presented to clinic for evaluation of a crop of vesicular lesions that were noted after removal of a bandage that had been in place for 4 days. A punch biopsy of the lesion revealed fungal elements that were later identified as Rhizopus spp. The lesion began to self‐resolve, and no further treatment was needed, with full resolution of the lesion by 1 month after presentation. Clinicians should be aware of the variable presentations of mucormycosis and consider fungal infection in the differential diagnosis when evaluating vulnerable patients with skin eruptions.     

Pathogenic role of IL-17 in psoriasis and psoriatic arthritis

Psoriasis is a chronic inflammatory skin disorder resulting from a complex network of cytokines and chemokines produced by various immune cell types and tissue cells. Emerging evidence suggests a central role of IL-17 and IL-23/T17 axis in the pathogenesis of psoriasis, giving a rationale for using IL-17-blocking agents as therapeutics.Three agents targeting IL-17 signaling are being studied in Phase III clinical trials: secukinumab and ixekizumab (IL-17 neutralizing agents), and brodalumab (IL-17 receptor antagonist). Preliminary results are highly promising for all anti-IL17 agents, creating fair expectations on this class of agents as the new effective therapeutic approach for the treatment of psoriasis.